SharkNinja (SN) FY Conference Summary Company Overview - SharkNinja operates in 37 product categories, including traditional items like vacuum cleaners and blenders, as well as innovative products like ice cream makers and espresso machines [2][4] - The company emphasizes consumer-centric innovation as a core strategy for growth [2][4] Financial Performance - SharkNinja reported a strong quarter with double-digit top-line growth each year since going public [4] - The company aims for a 14% top-line growth midpoint for the current year, following a 32% growth last year [39] Innovation Strategy - SharkNinja launches approximately 25 new products annually, focusing on creating product franchises rather than one-off hits [20][27] - The company uses consumer insights to guide product development, ensuring features align with consumer value [9][10] - Recent successful innovations include the slushy maker, which exceeded initial expectations and is seen as part of a broader franchise strategy [30][32] Supply Chain and Tariff Management - SharkNinja has been transitioning U.S. production out of China, aiming for 90% by the end of Q2 2025 and nearly 100% by year-end [15][18] - The company has invested in supply chain efficiency and cost management to mitigate tariff impacts, focusing on value engineering and consumer insights [8][13] International Expansion - The UK is the largest international market, with recent shifts to direct distribution models in Mexico and plans for further expansion in Europe [33][38] - SharkNinja is moving from a distributor model to owning distribution in several European countries, which is expected to enhance revenue and margins [36][38] Market Position and Consumer Health - SharkNinja does not compete at the low or high ends of the market but focuses on innovation and price value [51][52] - The company has not observed a slowdown in consumer spending, despite broader market concerns, and believes that innovation will help sustain its position during economic fluctuations [53] Key Takeaways - SharkNinja's growth strategy is built on three pillars: maintaining a strong base business, launching new products, and expanding internationally [39][43] - The company sees significant potential for growth in international markets and new product categories, indicating a robust outlook for future expansion [46][50]

Financial Data and Key Metrics Changes - Adjusted EBITDA was $113 million, down 19% year over year, or 10% excluding portfolio actions, driven by lower organic sales and production volume [7][15] - Sales for Q3 were $463 million, down 15% year over year, including a $53 million impact from portfolio optimization [14] - Adjusted EPS, excluding acquisition amortization, was $1.04, down 30% from the prior year [16] - Adjusted EBITDA margin was 24.4%, down 120 basis points [15] Business Line Data and Key Metrics Changes - Life Sciences sales were $162 million, down 17% year over year, primarily due to portfolio optimization initiatives [19] - Personal Care sales were $147 million, down 16% year over year, driven by portfolio optimization actions [25] - Specialty Additives sales declined 13% to $131 million, with organic sales and volumes both down 11% [30] - Intermediates generated $33 million in sales, down from $36 million in the same period last year [22] Market Data and Key Metrics Changes - Demand patterns remain mixed across the portfolio, with pharma steady and recovering, while personal care shows encouraging signs [42] - Specialty additives and intermediates are still facing headwinds, particularly in China [43] - Approximately 85% of the portfolio is tied to consumer end markets, many of which are non-cyclical and more resilient [11] Company Strategy and Development Direction - The company has completed its portfolio optimization and restructuring program, which remains ahead of schedule [12] - Focus on cost savings and operational discipline to support strong margins [6] - The company aims to drive differentiation and margin-accretive growth through innovation [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term opportunities despite current mixed demand [42] - The company is monitoring regulatory developments and does not anticipate a material direct impact on fiscal year results from tariff-related uncertainties [44] - Management highlighted the importance of maintaining a disciplined capital allocation strategy while focusing on productivity and innovation [49] Other Important Information - The company generated nearly 100% free cash flow conversion in the quarter, demonstrating the strength of its underlying business [8] - Liquidity at quarter end was over $800 million, providing flexibility for strategic investments [17] Q&A Session Summary Question: Insights on fiscal year 2026 and market recovery - Management discussed the cleaner portfolio and stable demand expected in personal care and pharma, with potential upside in specialty additives depending on market conditions [54][56] Question: Clarification on cost savings and restructuring - Management confirmed that restructuring and network optimization actions are complete, with expected savings flowing through to the P&L [78][80] Question: Stability in personal care markets - Management noted stability in mass brands, while the prestige segment has shown variability, particularly in biofunctional actives [70][72] Question: Near-term sales guidance and segment performance - Management indicated expectations for a sales increase in Q4 driven by specific portfolio activities, particularly in personal care and pharma [95][98]

Core Viewpoint - The successful listing of the Amova E Fund ChiNext Index ETF on the Singapore Exchange (SGX) provides investors with a new channel to capitalize on growth opportunities driven by innovation in China [1][2] Group 1: Product Overview - The Amova E Fund ChiNext Index ETF is the first Singapore ETF hedged in Singapore dollars, offering exposure to high-growth, innovative companies listed on the Shenzhen Stock Exchange [1] - The ETF is managed by Nikko Asset Management and focuses on key industries that drive China's economic transformation towards high value-added sectors, including technology, healthcare, and advanced manufacturing [1] Group 2: Market Context - The launch of this ETF aligns with the increasing market interest in China's innovation and growth themes, enhancing the range of A-share ETFs available under the SGX and Shenzhen Stock Exchange mutual fund scheme [2] - The ChiNext Index targets the 100 largest and most liquid growth companies in China, closely aligned with national strategic priorities such as digitalization, green energy, and industrial upgrading [1] Group 3: Impact on SGX - The successful listing of the Amova E Fund ChiNext Index ETF increases the total number of ETFs listed on SGX to 48, with total assets under management (AUM) exceeding 14 billion Singapore dollars [2]

Financial Data and Key Metrics Changes - The company authorized an additional $7.5 billion in shares for its accelerated buyback program, representing 21% of outstanding equity [3][4] - Operating cash flows reached over $141 million, the highest for the first quarter, with free cash flows totaling $107 million for the quarter and $620 million for the trailing twelve months [12] - The company has successfully reduced its leverage from three times to two times over the past two years, maintaining a strong balance sheet [12] Business Line Data and Key Metrics Changes - The residential segment saw growth primarily due to outdoor products, with margins holding well [16] - The commercial foodservice business experienced success from investments in the ice and beverage platform, although muted buying levels from major chain customers offset some gains [14] - Food processing revenues dropped due to customer-driven delivery delays, but the company anticipates higher sequential revenue in Q2 [15][19] Market Data and Key Metrics Changes - The company is facing tariff-related costs estimated to increase annual expenses by approximately $150 million to $200 million, with a significant portion attributed to foreign-sourced componentry from China [6][18] - The company expects to offset tariff impacts by the end of the year through operational actions and pricing adjustments [7][18] Company Strategy and Development Direction - The company plans to separate its food processing business into a standalone public company by early 2026, aiming to unlock shareholder value and enhance strategic focus [4][5] - The company is focusing on market expansion opportunities in adjacent markets such as poultry, pet foods, and snacks [5][22] - Strategic investments have been made to drive sustainable long-term growth, particularly in automation, digital technologies, and IoT connectivity [8][10] Management's Comments on Operating Environment and Future Outlook - Management acknowledges challenging market conditions affecting major chain customers but remains optimistic about sequential revenue increases throughout the year [17][20] - The company is confident in its ability to navigate tariff challenges and believes it is well-positioned to capitalize on market opportunities [7][45] - The long-term outlook for the food processing segment remains bullish, with a robust pipeline of opportunities [21][24] Other Important Information - The company plans to hold a dedicated Shareholder Day in Q4 to present further details on the strategic roadmap for the food processing business [6] - The company has received multiple industry awards for its innovative products, highlighting its commitment to innovation [10][99] Q&A Session Summary Question: 2025 sales guidance and segment outlook - Management indicated that the full-year outlook is primarily driven by the commercial segment, with expectations for improvement over the year despite current challenges [30][32] Question: Buyback decision rationale - The buyback decision was influenced by the company's strong cash flow, balance sheet position, and belief that the current share price does not reflect the business's strength [39][41] Question: Tariff impact and share gains - Management expressed confidence in offsetting tariff costs through operational initiatives and highlighted opportunities for share gains due to a strong U.S. manufacturing footprint [44][46] Question: Segment-level tariff cost allocation - The estimated tariff impact is weighted more towards commercial (approximately 70%), followed by residential (20%), and food processing (10%) [53] Question: Revenue outlook and new store openings - Management expects sequential improvement in revenue for Q2 and noted that new store openings are anticipated to be higher in the second half of the year [62] Question: Competitive pricing landscape - The company has observed competitors implementing price increases ranging from 10% to 25%, while it plans a mid-single-digit increase [83]

Core Viewpoint - The company reported a positive operational recovery in Q1 2025, with revenue and net profit showing sequential growth despite industry adjustments [1][2] Financial Performance - In Q1 2025, the company achieved revenue of 663 million yuan and a net profit of 444 million yuan, reflecting a quarter-on-quarter increase of 2.06% and 19.26% respectively [1] - The gross margin remained high at 93.85%, indicating strong pricing power amid competitive pressures [1] Product Development and Innovation - The company invested 58.54 million yuan in R&D, accounting for 8.82% of revenue, which is an increase of 1.65% year-on-year [1] - A new product, a domestic jaw filler, is expected to launch soon, leveraging its safety and support features to enhance performance in the second half of the year [1] Global Expansion Strategy - The company is accelerating its global market presence by acquiring 85% of REGEN Biotech Inc. for approximately 190 million USD, which will enhance its access to high-end regenerative products [2] - The new production facility in South Korea will alleviate capacity constraints and facilitate product penetration in 34 countries [2] Financial Health - As of March 2025, the company had cash reserves of 3.546 billion yuan, a significant increase of 134.10% from the end of 2024, and total equity exceeding 8.393 billion yuan [2] - The company’s total liabilities decreased by 17.29% compared to the end of 2024, indicating a healthy financial structure [2] Industry Context - The medical aesthetics industry is facing challenges from supply-side reforms and extended consumer decision cycles, but the company’s diversified strategies in R&D, globalization, and financial stability position it for long-term growth [2]

Financial Data and Key Metrics Changes - The company achieved 11% organic revenue growth in 2024, marking the second consecutive year of double-digit organic growth [5][10] - Adjusted operating income grew by 41%, and adjusted diluted earnings per share increased by 21% [11] - Free cash flow for the full year 2024 was $163 million, representing a 70% increase from the prior year [34] Business Line Data and Key Metrics Changes - Cardiopulmonary segment revenue for Q4 was $182 million, an 11% increase year-over-year, with full-year revenue of $684 million, growing 14% [11][13] - Epilepsy revenue increased by 1% in Q4, with U.S. epilepsy revenue growing by 4% year-over-year [15][16] - The company expects cardiopulmonary revenue to grow by 7% to 8% in 2025 and global epilepsy revenue to grow by 4% to 5% [13][17] Market Data and Key Metrics Changes - The hypoglossal nerve stimulation market for obstructive sleep apnea is expected to approach $2 billion by the end of the decade [7] - The company noted a growing worldwide prevalence of obstructive sleep apnea, with significant unmet needs in the market [60] Company Strategy and Development Direction - The company is focusing on innovation and growth, with a clear strategy to enhance its talent and culture [8][40] - Investment will be increased to accelerate product development in obstructive sleep apnea and difficult-to-treat depression [7][26] - The company aims to leverage its clinical and scientific expertise to expand into new therapeutic areas [6][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to continue delivering strong financial results and achieving significant milestones in innovation [5][40] - The company is optimistic about the future growth potential in both core and new markets, driven by strong clinical data and market demand [60][100] Other Important Information - The company plans to submit a PMA for obstructive sleep apnea in the first half of 2025, with a limited commercial launch expected thereafter [63] - Adjusted free cash flow is projected to be between $135 million and $155 million for 2025, reflecting increased capital spending [36] Q&A Session Summary Question: Can you help us understand the U.S. and EU cardiopulmonary performance in the quarter? - Management acknowledged a challenging comparison due to previous high growth but noted sequential growth in HLM placements and strong demand for consumables [46] Question: What is the impact of the launch of the new ECMO related product? - Management highlighted that innovation is a key focus and expects the new product to drive growth in 2025 [50][57] Question: How much are you spending to prepare for the sleep apnea launch? - The company invested $27 million in 2024 and plans to invest an additional $8 million in 2025, shifting focus from clinical spend to product development [61] Question: What are the execution issues in the OUS epilepsy business? - Management identified personnel issues as isolated across different markets and expressed confidence in returning to growth [66] Question: Can you provide insight into revenue phasing for 2025? - Management indicated that Q1 is typically the lowest quarter, with growth expected to ramp up throughout the year [69] Question: What is the expected impact of the Siena ruling? - Management stated that they do not anticipate a decision at the upcoming hearing but expect a ruling in the first half of 2025 [78] Question: How does the company view capital allocation between core business and new initiatives? - Management emphasized the importance of sustaining growth in core businesses while also investing in new growth opportunities [100]